Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Genenta's Success in Reprogramming GBM Tumor Microenvironment Opens New Paths for Solid Tumor Treatments
Pharma Pioneer
2 min read
Genenta's Success in Reprogramming GBM Tumor Microenvironment Opens New Paths for Solid Tumor Treatments
29 May 2024
Genenta Science, a clinical-stage biotech firm specializing in immuno-oncology, has made significant progress in its Phase 1/2 clinical trial for Temferon™.
Read →
Belhaven Biopharma Reveals Promising Nasdepi Trial Outcomes: A Needle-Free Epinephrine Solution for Severe Allergies
Pharma Pioneer
2 min read
Belhaven Biopharma Reveals Promising Nasdepi Trial Outcomes: A Needle-Free Epinephrine Solution for Severe Allergies
29 May 2024
Belhaven Biopharma announced promising results from its Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis due to severe allergic reactions.
Read →
FDA Approves Hemogenyx's Phase I HEMO-CAR-T Trials
Pharma Pioneer
3 min read
FDA Approves Hemogenyx's Phase I HEMO-CAR-T Trials
29 May 2024
Hemogenyx Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) to commence Phase I clinical trials for its innovative HEMO-CAR-T treatment for acute myeloid leukemia (AML).
Read →
HMB-001 Phase 1 Success in Glanzmann Thrombasthenia Showcased at EAHAD 2024
Pharma Pioneer
2 min read
HMB-001 Phase 1 Success in Glanzmann Thrombasthenia Showcased at EAHAD 2024
29 May 2024
HMB-001, a novel bispecific antibody developed by Hemab Therapeutics, has shown promising results in Phase 1 clinical trials for treating Glanzmann Thrombasthenia.
Read →
Anixa Begins Higher Dose Phase in Ovarian Cancer CAR-T Trial
Pharma Pioneer
2 min read
Anixa Begins Higher Dose Phase in Ovarian Cancer CAR-T Trial
29 May 2024
Anixa Biosciences has initiated treatment for a fourth participant in its Phase 1 clinical trial for a new CAR-T cell therapy aimed at ovarian cancer.
Read →
Nuvalent Starts Phase 2 of ALKOVE-1 Trial for ALK-Positive NSCLC and Solid Tumors
Pharma Pioneer
2 min read
Nuvalent Starts Phase 2 of ALKOVE-1 Trial for ALK-Positive NSCLC and Solid Tumors
29 May 2024
Nuvalent has commenced the Phase 2 stage of the ALKOVE-1 clinical trial for NVL-655, a novel ALK-selective tyrosine kinase inhibitor (TKI).
Read →
Protagenic Therapeutics Hits Safety Milestone in Phase I Trial for Stress-Related Disorders Treatment
Pharma Pioneer
2 min read
Protagenic Therapeutics Hits Safety Milestone in Phase I Trial for Stress-Related Disorders Treatment
29 May 2024
Protagenic Therapeutics, Inc. has made progress in its clinical trial for a new brain peptide compound called PT00114.
Read →
EyeBio Presents Favorable Restoret Trial Results at Macula Society Meeting
Pharma Pioneer
3 min read
EyeBio Presents Favorable Restoret Trial Results at Macula Society Meeting
29 May 2024
The Phase 1b/2a AMARONE clinical trial's 12-week results indicate that Restoret, developed by Eyebiotech Limited, is well-tolerated in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).
Read →
First Patient Treated in ABILITY-1 Trial of MDNA11 Plus KEYTRUDA® for Advanced Solid Tumors
Pharma Pioneer
3 min read
First Patient Treated in ABILITY-1 Trial of MDNA11 Plus KEYTRUDA® for Advanced Solid Tumors
29 May 2024
Medicenna Therapeutics has initiated a Phase 1/2 clinical trial, known as the ABILITY-1 study, to assess the safety and efficacy of MDNA11, a modified version of interleukin-2 (IL-2).
Read →
Early Positive Outcomes in Phase 1 Deltacel-01 Trial Show Tumor Shrinkage
Pharma Pioneer
2 min read
Early Positive Outcomes in Phase 1 Deltacel-01 Trial Show Tumor Shrinkage
29 May 2024
A recent clinical study by Kiromic BioPharma, Inc. has shown positive results in the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) with their drug candidate, Deltacel™.
Read →
First Patient Receives Samuraciclib-Vepdegestrant Combo in Advanced Breast Cancer Trial
Pharma Pioneer
2 min read
First Patient Receives Samuraciclib-Vepdegestrant Combo in Advanced Breast Cancer Trial
29 May 2024
Carrick Therapeutics has initiated a Phase 1b/2 clinical trial to test the efficacy and safety of a combined treatment of samuraciclib (CT7001) and vepdegestrant (ARV-471) in patients.
Read →
First Patient Treated in Phase 1b/2 Pancreatic Cancer Trial with AIM's Ampligen® and AstraZeneca's Imfinzi®
Pharma Pioneer
2 min read
First Patient Treated in Phase 1b/2 Pancreatic Cancer Trial with AIM's Ampligen® and AstraZeneca's Imfinzi®
29 May 2024
AIM ImmunoTech Inc. has initiated a Phase 1b/2 clinical trial at Erasmus Medical Center for patients with advanced pancreatic cancer.
Read →